SURVIVAL IN CHILDREN AND ADOLESCENTS (C plus A) WITH MATURE B-NHL PROGRESSING OR RELAPSING FROM TREATMENT ON FAB/LMB 96: TUMOR BURDEN AND TIME TO RELAPSE ARE POOR PROGNOSTIC FACTORS

被引：0
|
作者：
Cairo, Mitchell S. [1 ]
Sposto, Richard [2 ]
Fan, Jin [2 ]
Gerrard, Mary [3 ]
Auperin, Anne [4 ]
Pinkerton, Ross [5 ]
McCarthy, Keith [6 ]
Raphael, Martine [7 ]
Harrison, Lauren [1 ]
Goldman, Stanton [8 ]
Patte, Catherine [4 ]
机构：
[1] Columbia Univ, New York, NY USA
[2] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA
[3] Sheffield Childrens Hosp, Sheffield, S Yorkshire, England
[4] Inst Gustave Roussy, Villejuif, France
[5] Royal Childrens Hosp, Parkville, Vic, Australia
[6] Gloucestershire Hosp NHS Fdn Trust, Gloucester, England
[7] Hop Bicetre, AP HP, Paris, France
[8] Med City Childrens Hosp, Dallas, TX USA
来源：
PEDIATRIC BLOOD & CANCER | 2009年 / 53卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：855 / 855
页数：1
相关论文
共 13 条
  • [1] RESULTS OF THE ADDITION OF RASBURICASE(RU) AND RITUXMAB(RM) TO THE FAB/LMB96 CHEMOTHERAPY BACKBONE IN CHILDREN plus ADOLESCENTS(C plus A) WITH MATURE B-NHL:A CHILDREN'S ONCOLOGY GROUP REPORT
    Cairo, Mitchell S.
    Lynch, James
    Harrison, Lauren
    Perkins, Sherrie
    Sanger, Warren
    Gross, Thomas
    Shiramizu, Bruce
    Goldman, Stanton
    PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 858 - 858
  • [2] Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy
    Gerrard, Mary
    Waxman, Ian M.
    Sposto, Richard
    Auperin, Anne
    Perkins, Sherrie L.
    Goldman, Stanton
    Harrison, Lauren
    Pinkerton, Ross
    McCarthy, Keith
    Raphael, Martine
    Patte, Catherine
    Cairo, Mitchell S.
    BLOOD, 2013, 121 (02) : 278 - 285
  • [3] Poor response to initial reduction therapy (COP) and combined bone marrow and CNS disease are poor prognostic factors in children with advanced (BM±CNS) B-NHL treated on the international study FAB/LMB96.
    Cairo, MS
    Gerrard, M
    Sposto, R
    Auperin, A
    Pinkerton, R
    Michon, J
    Perkins, S
    Raphael, M
    McCarthy, K
    Weston, C
    Patte, C
    BLOOD, 2003, 102 (11) : 143A - 143A
  • [4] Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group
    Cairo, Mitchell
    Auperin, Anne
    Perkins, Sherrie L.
    Pinkerton, Ross
    Harrison, Lauren
    Goldman, Stanton
    Patte, Catherine
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (06) : 859 - 869
  • [5] Advanced stage, elevated LDH, primary sites, but not adolescent (A) age (≥ 15 years) as risk factors for disease progression in childhood (C) and adolescent (A) mature B-NHL: Report of the FAB/LMB 96 international trial
    Cairo, M. S.
    Sposto, R.
    Gerrard, M.
    Waxman, I.
    Goldman, S.
    Auperin, A.
    Pinkerton, R.
    Raphael, M.
    McCarthy, K.
    Perkins, S. L.
    Patte, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Excellent outcomes in children and adolescents with CNS+ Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1
    Frazer, J. Kimble
    Li, Kevin J.
    Galardy, Paul J.
    Perkins, Sherrie L.
    Auperin, Anne
    Anderson, James R.
    Pinkerton, Ross
    Buxton, Allen
    Gross, Thomas G.
    Michon, Jean
    Leverger, Guy
    Weinstein, Howard J.
    Harrison, Lauren
    Shiramizu, Bruce
    Barth, Mathew J.
    Goldman, Stanton C.
    Patte, Catherine
    Cairo, Mitchell S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (02) : 374 - 377
  • [7] Prognostic Factors and Treatment Outcome of Relapsing Mature B Cell Non Hodgkin Lymphoma Treated According to LMB96 Protocol at the Children Cancer Hospital Egypt
    Rahman, H. Abdel
    Hamoda, A.
    Moussa, E.
    Talaat, S.
    El Wakeel, M.
    Amin, R.
    Yasser, N.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S175 - S176
  • [8] Prognostic Factors and Treatment Outcome of Relapsing Mature B Cell Non Hodgkin Lymphoma Treated According to LMB96 Protocol at the Children Cancer Hospital Egypt
    Hamoda, A.
    Abdelrahman, H.
    Moussa, E.
    Talaat, S.
    Amin, R.
    Elwakeel, M.
    Yasser, N.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S200 - S201
  • [9] Prognostic factors and treatment outcome of relapsing mature B cell Non-Hodgkin lymphoma treated according to LMB96 protocol at the Children Cancer Hospital Egypt
    Rahman, Hany Abdel
    Moussa, Emad
    Hamoda, Asmaa
    Talaat, Sally
    Amin, Randa
    El Wakeel, Madeha
    Yasser, Nouran
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 : 98 - 98
  • [10] Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C plus A) with stage III/IV (Group B) and BM plus /CNS plus (Group C) mature B-NHL: A Children's Oncology Group report.
    Cairo, M. S.
    Lynch, J. C.
    Harrison, L.
    Perkins, S. L.
    Shiramizu, B.
    Gross, T. G.
    Sanger, W.
    Goldman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12